Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation - SPORTIF II


The goal of the SPORTIF II trial was to determine the tolerability and safety of a novel, oral direct thrombin inhibitor ximelagatran versus warfarin for prevention of stroke and systemic embolic events in patients with nonvalvular atrial fibrillation (NVAF) and at least one additional risk factor for stroke.